01873.HK
Viva Biotech Holdings
HKSE · Healthcare · Biotechnology · CN
HKD 1.34
−2.20%Year over year
Reported trailing growth
- Revenue
- -15.5%
- EBITDA
- -5.7%
- EBIT
- -13.6%
- EPS
- +171.1%
- Free cash flow
- +24.6%
- Operating cash flow
- -6.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -10.1%
- EBITDA
- -4.1%
- EBIT
- -10.5%
- Net income
- +31.4%
- EPS
- +14.9%
- Free cash flow
- -13.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026